Skip to main content

Table 3 Antimalarial treatments for patients who needed management with AL as defined by national guidelines

From: Malaria case-management under artemether-lumefantrine treatment policy in Uganda

All health facilities < 5 years (N = 461) ≥ 5 years (N = 739) All patients (N = 1200)
  n (%) 95% CI n (%) 95% CI n (%) 95% CI
   AL 306 (66.4) 61.1–71.7 415 (56.2) 50.3–62.0 721 (60.1) 55.6–64.6
   CQ+SP 35 (7.6) 4.8–10.4 133 (18.0) 13.2–22.8 168 (14.0) 10.7–17.3
   Quinine 27 (5.9) 3.1–8.6 21 (2.8) 1.4–4.3 48 (4.0) 2.6–5.4
   Chloroquine 10 (2.2) 0.7–3.6 22 (3.0) 1.4–4.6 32 (2.7) 1.5–3.9
   SP 2 (0.4) 0–1.0 7 (1.0) 0–2.1 9 (0.8) 0–1.5
   Other antimalarial treatments* 16 (3.5) 1.4–5.6 14 (1.9) 0.5–3.3 30 (2.5) 1.2–3.8
   No antimalarial prescribed 65 (14.1) 10.8–17.4 127 (17.2) 13.9–20.5 192 (16.0) 13.5–18.5
Facilities with AL in stock < 5 years (N = 428) ≥ 5 years (N = 644) All patients (N = 1072)
  n (%) 95% CI n (%) 95% CI n (%) 95% CI
   AL 297 (69.4) 64.2–74.6 388 (60.3) 54.2–66.3 685 (63.9) 59.5–68.3
   CQ+SP 22 (5.1) 2.8–7.5 95 (14.8) 10.1–19.4 117 (10.9) 8.0–13.9
   Quinine 22 (5.1) 2.4–7.9 16 (2.5) 1.0–4.0 38 (3.5) 2.2–4.9
   Chloroquine 9 (2.1) 0.6–3.6 16 (2.5) 0.8–4.2 25(2.3) 1.1–3.6
   SP 2 (0.5) 0–1.1 6 (0.9) 0–2.2 8 (0.8) 0–1.6
   Other antimalarial treatments 15 (3.5) 1.3–5.7 12 (1.9) 0.3–3.4 27 (2.5) 1.1–4.0
   No antimalarial prescribed 61 (14.3) 10.8–17.7 111 (17.2) 13.8–20.7 172 (16.0) 13.4–18.7
  1. * Other antimalarial treatments include artemether (2), AQ+SP (2), AL+SP (8), AL+CQ+SP (2), QN+SP (6), AL+QN (4), AL+CQ (6)
  2. † Other antimalarial treatments include artemether (1), AQ+SP (2), AL+SP (8), AL+CQ+SP (2), QN+SP (6), AL+QN (3), AL+CQ (5)